eligibility_summary
Eligible: histology-confirmed DLBCL (no CNS), age ≥80 or 70–79 and unfit/frail, IPI 2–5, measurable disease, can swallow, life expectancy ≥3 months, consent, no prior anti-lymphoma drugs (steroids allowed). Exclude: uncontrolled coagulopathy/infection/CTD, key lab abnormalities, eGFR<40, major cardiac disease (LVEF<50%, QTc↑, AV block, cardiomyopathy), HBV DNA ≥1×10^3 IU/ml, psychiatric noncompliance, HIV+, stroke/ICH <6 mo, other concerning conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized trial in elderly de novo DLBCL comparing Pola‑ZR2 (polatuzumab vedotin + zanubrutinib + rituximab + lenalidomide) versus ZR2 (zanubrutinib + rituximab + lenalidomide), with lenalidomide maintenance for responders. Drug types and mechanisms: polatuzumab vedotin—anti‑CD79b antibody‑drug conjugate delivering MMAE (microtubule inhibitor) to B cells, zanubrutinib—small‑molecule, covalent BTK inhibitor blocking B‑cell receptor (BCR) signaling, rituximab—chimeric anti‑CD20 monoclonal antibody inducing B‑cell depletion via ADCC, CDC, and apoptosis, lenalidomide—immunomodulatory drug (IMiD) enhancing T/NK activity, cereblon‑mediated degradation of Ikaros/Aiolos, anti‑angiogenic and direct antitumor effects. Targets/pathways: malignant CD20+/CD79b+ B cells, BCR‑BTK signaling, microtubules, complement and Fc‑mediated cytotoxicity, and tumor‑immune microenvironment.